{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-145197","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.692338+00:00","generated_at":"2026-06-15T01:25:40.757070+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha completes screening for Rett syndrome gene therapy trial; reports Q1 net loss of $17.6M","bullets":["Screening completed for first adult patient in Phase 1/2 REVEAL trial of TSHA-102 for Rett syndrome; dosing expected Q2 2023.","Initial available Phase 1/2 clinical data, primarily on safety, expected in Q2 2023.","Net loss for Q1 2023 was $17.6M ($0.28 per share) vs. $50.3M ($1.32 per share) in Q1 2022.","Cash and equivalents $63.4M as of March 31, 2023; expected to fund operations into Q1 2024.","FDA meeting request for TSHA-120 (GAN) regulatory path expected Q2 2023; meeting anticipated Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-145197","json":"https://secwatch.observer/filing/0001193125-23-145197.json","markdown":"https://secwatch.observer/filing/0001193125-23-145197.md","text":"https://secwatch.observer/filing/0001193125-23-145197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/0001193125-23-145197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/d431505d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:25:40.757070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f390b2d377d3369ee1daab0e4c97b209b939c70","claim":"Taysha Gene Therapies, Inc. reported financial results for quarter ended March 31, 2023.","evidence_excerpt":"Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523145197/0001193125-23-145197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}